Oncolytics Biotech Inc ONCY Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.44 down $0.01, 2.09% at close Nov 6
Last close · Previous close $0.45
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.34Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.44down $0.16, 26.52%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.45Nov 5
- Volume516.95KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.38MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.38 to $1.30; now $0.44
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ONCY trailed the S&P 500 in all 6 periods.
| Period | ONCY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ONCY: down 26.5% S&P 500: down 5.6% | ONCY trailed the S&P 500 by 20.9 percentage points Trailed |
| 3M | ONCY: down 45.1% S&P 500: down 4.1% | ONCY trailed the S&P 500 by 41.0 percentage points Trailed |
| YTD | ONCY: down 49.7% S&P 500: up 8.7% | ONCY trailed the S&P 500 by 58.4 percentage points Trailed |
| 1Y | ONCY: down 56.5% S&P 500: up 10.9% | ONCY trailed the S&P 500 by 67.4 percentage points Trailed |
| Long term | ||
| 3Y | ONCY: down 73.0% S&P 500: up 75.0% −35.4% vs +20.5% a year | ONCY trailed the S&P 500 by 148.0 percentage points Trailed |
| 5Y | ONCY: down 79.1% S&P 500: up 67.8% −26.9% vs +10.9% a year | ONCY trailed the S&P 500 by 146.9 percentage points Trailed |
$10,000 invested in ONCY 5 years ago (Nov 5, 2021) would be worth about $2,092 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
ONCY trailed the S&P 500 in all 6 periods.
| Period | ONCY and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ONCY: down 26.5% S&P 500: down 5.6% | ONCY trailed the S&P 500 by 20.9 percentage points Trailed |
| 3M | ONCY: down 45.1% S&P 500: down 4.3% | ONCY trailed the S&P 500 by 40.8 percentage points Trailed |
| YTD | ONCY: down 49.7% S&P 500: up 7.8% | ONCY trailed the S&P 500 by 57.5 percentage points Trailed |
| 1Y | ONCY: down 56.5% S&P 500: up 9.7% | ONCY trailed the S&P 500 by 66.2 percentage points Trailed |
| Long term | ||
| 3Y | ONCY: down 73.0% S&P 500: up 68.8% −35.4% vs +19.1% a year | ONCY trailed the S&P 500 by 141.8 percentage points Trailed |
| 5Y | ONCY: down 79.1% S&P 500: up 56.9% −26.9% vs +9.4% a year | ONCY trailed the S&P 500 by 136.0 percentage points Trailed |
$10,000 invested in ONCY 5 years ago (Nov 5, 2021) would be worth about $2,092 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$7.20
Closing high on . Now 93.9% below that record.
Split-adjusted daily closes since May 31, 2018.
Stock splits
ONCY hasn’t split since its price history begins in 2018.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$38.13M
- Diluted EPS
- −$0.34
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$6.92M | −$0.09 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$5.62M | −$0.08 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$4.71M | −$0.06 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$5.28M | −$0.06 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$10.44M | −$0.10 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$9.00M | −$0.08 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$9.24M | −$0.08 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$9.44M | −$0.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$19.07M | −$0.36 |
| FY22 (Dec 31, 2022) | $0.00 | −$18.01M | −$0.31 |
| FY23 (Dec 31, 2023) | $0.00 | −$20.12M | −$0.30 |
| FY24 (Dec 31, 2024) | $0.00 | −$22.79M | −$0.30 |
| FY25 (Dec 31, 2025) | $0.00 | −$28.76M | −$0.30 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$26.88MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$26.87MLast 12 months
- Capital spending$12.00KLast 12 months
Shareholder returns
- $20.22MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $4.12MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$448.00KAs of Jun 30, 2026
- Net cash$3.67MAs of Jun 30, 2026
- 1.35As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −444.2%Last 12 months
Over the last 12 months, Oncolytics Biotech’s net loss was 444.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Oncolytics Biotech Inc
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, of which both development programs have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @ oncolytics. Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Alberta, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ONCY news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ONCY stock FAQ
What is ONCY stock’s price today?
Oncolytics Biotech (ONCY) traded at $0.44 at the close on , down $0.01 (2.09%) from the previous close of $0.45. Over the past 52 weeks it has traded between $0.38 and $1.30.
If you invested $1,000 in ONCY 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ONCY on would be worth about $209 at the close on , a total return of −79.1%. The same $1,000 would be worth $435 if invested one year ago. Past performance doesn’t predict future returns.
What is ONCY’s P/E ratio?
ONCY’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.34).
What are ONCY’s earnings per share?
ONCY’s diluted earnings per share were −$0.34 over the four quarters to , compared with −$0.28 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.08 per share, against −$0.06 a year earlier (how EPS works).
Does ONCY pay a dividend?
Oncolytics Biotech hasn’t paid a dividend in the last twelve months.
What is ONCY’s 52-week high and low?
Over the past 52 weeks ONCY has traded as low as $0.38 and as high as $1.30. At $0.44 at the close on , it is 66.2% below that high and 15.1% above the low.
What is ONCY’s all-time high?
ONCY’s highest closing price was $7.20 on , adjusted for stock splits. At $0.44 at the close on , it is 93.9% below that record.
Has ONCY stock ever split?
No. ONCY hasn’t split since its price history begins in 2018.
How has ONCY stock performed?
Including dividends and measured to the close on , ONCY has returned −49.7% so far this year and −56.5% over the past year, and −79.1% over five years (−26.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Oncolytics Biotech in?
Oncolytics Biotech is in the Healthcare sector and the Biotechnology industry, and is headquartered in Alberta, Canada.
What exchange does ONCY trade on?
Oncolytics Biotech trades on the Nasdaq under the ticker symbol ONCY. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.